Therapeutic combination

a combination and therapy technology, applied in the field of therapeutic combination, can solve the problems of adverse cardiac events, adverse cardiac events, and failure to demonstrate full normalization of cardiovascular mortality in hypertension intervention trials, and achieve the effect of substantially reducing the risk of future adverse cardiac events

Inactive Publication Date: 2006-10-05
BUCH JAN +1
View PDF23 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0141] Where used herein, the term “cardiac risk”means, the likelihood that a subject will suffer a future adverse cardiac event such as, e.g., myocardial infarction, cardiac arrests cardiac failure, cardia

Problems solved by technology

Patients who undergo PTCA or other surgical procedures designed to treat angina pectoris frequently experience complications such as restenosis.
Hypertension frequently coexists with hyperlipidemia and both are considered to be major risk factors for developing cardiac disease ultimat

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Therapeutic combination
  • Therapeutic combination
  • Therapeutic combination

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0142] The pharmaceutical compositions of this invention comprise amlodipine or a pharmaceutically acceptable acid addition salt thereof and / or atorvastatin or a pharmaceutically acceptable salt thereof.

[0143] Amlodipine may readily be prepared as described in U.S. Pat. No. 4,572,909 which is incorporated herein by reference. Amlodipine besylate, which is currently sold as Norvasc®, may be prepared as described in U.S. Pat. No. 4,879,303, which is incorporated herein by reference. Amlodipine and amlodipine besylate are potent and long lasting calcium channel blockers.

[0144] The expression “pharmaceutically-acceptable acid addition salts”is intended to define but is not limited to such salts as the hydrochloride, hydrobromide, sulfate, hydrogen sulfate, phosphate, hydrogen phosphate, dihydrogenphosphate, acetate, besylate, succinate, citrate, methanesulfonate (mesylate) and p-toluenesulfonate (tosylate) salts.

[0145] Other acid addition salts of amlodipine may be prepared by reacti...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Massaaaaaaaaaa
Massaaaaaaaaaa
Massaaaaaaaaaa
Login to view more

Abstract

This invention relates to pharmaceutical combinations of amlodipine or a pharmaceutically acceptable acid addition salt thereof and atorvastatin or a pharmaceutically acceptable salt thereof, kits containing such combinations and methods of using such combinations to treat subjects suffering from angina pectoris, atherosclerosis, combined hypertension and hyperlipidemia and to treat subjects presenting with symptoms of cardiac risk, including humans. This invention also relates to additive and synergistic combinations of amlodipine and atorvastatin whereby those synergistic combinations are useful in treating subjects suffering from angina pectoris, atherosclerosis, combined hypertension and hyperlipidemia and those subjects presenting with symptoms of cardiac risk, including humans.

Description

[0001] This invention relates to pharmaceutical combinations of amlodipine and pharmaceutically acceptable acid addition salts thereof and atorvastatin and pharmaceutically acceptable salts thereof, kits containing such combinations and methods of using such combinations to treat subjects suffering from angina pectoris, atherosclerosis, combined hypertension and hyperlipidemia and to treat subjects presenting with symptoms of cardiac risk, including humans. This invention also relates to additive and synergistic combinations of amlodipine and atorvastatin whereby those additive and synergistic combinations are useful in treating subjects suffering from angina pectoris, atherosclerosis, combined hypertension and hyperlipidemia and those subjects presenting with symptoms or signs of cardiac risk, including humans. BACKGROUND OF THE INVENTION [0002] The conversion of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) to mevalonate is an early and rate-limiting step in the cholesterol bios...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/455A61K31/401A61K9/00A61K31/40A61K31/435A61K31/44A61K31/4422A61K39/39A61K47/26A61K47/40A61P3/06A61P7/02A61P9/10A61P9/12A61P37/04A61P43/00
CPCA61K9/0019A61K31/40A61K31/435A61K31/44A61K31/4422A61K47/26A61K47/40A61K2039/55577A61K39/39A61K2300/00A61P11/06A61P3/06A61P37/04A61P43/00A61P7/02A61P9/00A61P9/10A61P9/12Y02A50/30
Inventor BUCH, JANSCOTT, ROBERT ANDREW DONALD
Owner BUCH JAN
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap